NEW YORK, NY — December 30, 2025 — Leads & Copy — PAVmed Inc. (NASDAQ: PAVM) has announced a 1-for-30 reverse stock split of its common stock, effective January 2, 2026, at 12:01 a.m. Eastern Time.
The company’s common stock will continue trading on the Nasdaq Capital Market under the symbol “PAVM” and will begin trading on a split-adjusted basis at the opening of the market on January 2, 2026. The reverse stock split aims to meet the $1.00 minimum bid price requirement for maintaining its listing on Nasdaq.
The reverse stock split was approved by the company’s stockholders during a special meeting held on December 5, 2025. The ratio was determined at the discretion of the company’s board of directors within approved parameters and finalized on December 8, 2025. Following the reverse stock split, the authorized shares of common stock will decrease from 250,000,000 to 25,000,000. This reduction was also approved by stockholders at the special meeting, contingent on the completion of the reverse stock split.
The number of shares available for issuance under the company’s equity incentive plan and employee stock purchase plan will be proportionately reduced. Additionally, the exercise prices and number of shares subject to the company’s outstanding stock options, and the conversion prices of outstanding convertible securities, including convertible debt and preferred stock, will be adjusted proportionally.
No fractional shares of common stock will be issued. Stockholders who would hold a fractional share due to the reverse stock split will have their holdings rounded up to the nearest whole share.
The new CUSIP number for the common stock after the reverse stock split will be 70387R 502.
PAVmed Inc. operates in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), focuses on cancer prevention through the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. Another subsidiary, Veris Health Inc., is a digital health company developing personalized cancer care solutions through remote patient monitoring using implantable biologic sensors and connected external devices.
For Lucid Diagnostics, please visit luciddx.com.
For Veris Health, please visit verishealth.com.
Source: PAVmed Inc.
